Date:8/12/2011

red government grant recognized in income(68,965)(65,855)(137,447)(131,685) - accretion expenses102,564-204,409-  - accounts receivable4,330,944(3,389,051)4,377,521(1,559,320)  - inventories(345,299)(4,705,960)(2,626,987)(8,477,709)  - income tax payable(402,540)(2,070,272)(505,933)(4,698,680)  - prepaid expenses and deposits(501,030)31,019(511,790)(304,751)  - deferred revenue and advances   from customers(3,014,970)(3,217,309)(3,317,650)(374,556)  - accounts payable and accrued liabilities(1,308,444)4,044,222(4,186,558)(5,133,166)Net cash provided by (used in) operating activities3,414,490(6,868,285)(4,276,777)(17,014,706)Cash flows from (used in) financing activities  - Loan proceeds1,881,372-1,881,3728,265,031  - Loan repayment(1,374,424)(14,777,424)(1,374,424)(14,777,424)  - Proceeds from issuance of common stock net of share issuance cost251,83947,395536,54861,915,101  - Repayment from (loan to) non-controlling shareholder of Sinovac Beijing-3,285,4643,397,522(3,286,695)  - Subscriptions received8,4804,8008,4804,800  - Dividends paid to non-controlling shareholder of-(3,285,902)(5,862,676)(3,285,902)Sinovac Beijing  - Due from non-controlling shareholder of  Sinovac Dalian-519,075-519,075  - Government grant received7,636189,0077,636235,818Net cash provided by (used in) financing activities774,903(14,017,585)(1,405,542)49,589,804Cash flows used in investing activities - Restricted cash-(302,038)-(244,077) - Proceeds from disposal of equipment-1,594-191,470 - Proceeds from redemption of short-term investments1,547,030-1,547,0307,314,187 - Purchase of short-term investments(22,431,931)(1,610,984)(22,431,931)(9,949,157) - Prepayments for acquisition of new facility---(8,265,031) - Acquisition of property, plant and equipment(4,544,793)(1,649,336)(5,698,141)(2,097,501)Net cash used in investing activities(25,429,694)(3,560,764)(26,583,042)(13,050,109)Exchange effect on cash and cash e
'/>"/>

SOURCE Sinovac Biotech Ltd. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine technology :

1. Sinovac Announces Management Changes
2. Sinovac Holds 2011 Annual Shareholders Meeting
3. Sinovac Appoints Kenneth Lee to Board of Directors
4. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
5. Sinovac Reports Unaudited First Quarter 2011 Financial Results
6. Sinovac Presents at Two Investor Conferences in May 2011
7. Sinovac Files Annual Report on Form 20-F
8. Sinovac Participates in UBS Greater China Healthcare Corporate Day
9. Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
10. Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV)
11. Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range